Reply: Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery

Brain

Volumn 133, Issue 11, 2010, Pages

  Thobois, Stephane ^a,b   Broussolle, Emmanuel ^a,b   Kombo, Magaly Aya ^c,d   Pollak, Pierre ^c,d   Krack, Paul ^c,d  

^a UNIVERSITÉ LYON 1   (France)

^b INSTITUT DES SCIENCES COGNITIVES   (France)

^c UNIV GRENOBLE ALPES   (France)

^d GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ANXIETY; APATHY; BRAIN DEPTH STIMULATION; DENERVATION; DEPRESSION; DYSKINESIA; HUMAN; IMPULSE CONTROL DISORDER; LETTER; PARKINSON DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

EID: 78049483254     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq166     Document Type: Letter

References (32)

1. Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki V, Hosseini H, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006; 21: 1941-6.
2. Barbeau A. L-Dopa therapy in Parkinsons disease: A critical review of nine years experience. Can Med Ass J 1969; 101: 791-800.
3. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010 [Epub ahead of print].
4. Czernecki V, Schupbach M, Yaici S, Levy R, Bardinet E, Yelnik J, et al. Apathy following subthalamic stimulation in Parkinson disease: A dopa-mine responsive symptom. Mov Disord 2008; 23: 964-9.
5. Evans AH, Lawrence AD, Cresswell SA, Katzenschlager R, Lees AJ. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward. Mov Disord 2010; 25: 867-76.
6. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59: 852-8.
7. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2547-9.
8. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant like syndrome due to levodopa therapy withdrawal. JAMA 1985; 254: 2792-5.
9. Funkiewiez A, Ardouin C, Caputo E, Krack P, Fraix V, Klinger H, et al. Long-term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 834-9.
10. Funkiewiez A, Ardouin C, Krack P, Fraix V, VanBlercom N, Xie J, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003; 18: 524-30.
11. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001; 411: 86-9.
12. Houeto JL, Mesnage V, Mallet L, Pillon B, Gargiulo M, Tezenas du Moncel S, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 701-7.
13. Krack P, Fraix V, Mendes A, Benabid AL, Pollak P. Postoperative management of subthalamic nucleus stimulation for Parkinson's disease. Mov Disord 2002; 17 (Suppl 3): 188-97.
14. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003; 2: 595-604.
15. Lim SY, O'Sullivan SS, Kotschet K, Gallagher DA, Lacey C, Lawrence AD, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009; 16: 1148-52.
16. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: A double-blind, placebo-controlled study. Neurology 1995; 45: 1757-60.
17. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five year follow up. J Neurol Neurosurg Psychiat 1994; 57: 1034-8.
18. Murray AM, Ryoo HL, Gurevich E, Joyce JN. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 1994; 91: 11271-5.
19. Nirenberg M. Dopamine agonist withdrawal syndrome and non-motor symptoms after Parksinon's disease surgery. Letter to the editor. Brain 2010 submitted.
20. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 11 (Suppl 5): S1-88.
21. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67: 58-63.
22. Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand 2001; 104: 312-5.
23. Sacks O. Awakenings. London: Pan Books Ltd; 1982.
24. Smeding HM, Goudriaan AE, Foncke EM, Schuurman PR, Speelman JD, Schmand B. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007; 78: 517-9.
25. Thobois S, Ardouin C, Lhommée E, Klinger H, Lagrange C, Xie-Brustolin J, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors, and underlying mesolimbic denervation. Brain 2010; 133: 1111-2.
26. Thobois S, Corvasier S, Mertens P, DiGuardo C, Mollion H, Guenot M, et al. The timing of antiparkinsonian treatment reduction after sub-thalamic nucleus stimulation. Eur Neurol 2003; 49: 59-63.
27. Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006; 67: 1254-7.
28. Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schupbach M, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008; 131: 2720-8.
29. Weintraub D. Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 2008; 64 (Suppl 2): S93-100.
30. Witjas T, Baunez C, Henry JM, Delfini M, Regis J, Cherif AA, et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005; 20: 1052-5.
31. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408-13.
32. Yahr MD, Duvoisin RC, Schear MJ, Barrett E, Hoehn MN. Treatment of Parkinsonism with levodopa. Arch Neurol 1969; 21: 343-54.